Citing pandemic, Sarepta defers much-anticipated DMD gene therapy PhIII, will head to regulators after 10-person study
When Sarepta disclosed in September that the FDA held up their widely-anticipated Phase III trial over an assay, the big question was whether the setback might allow Pfizer to overtake them in the heated race to develop a gene therapy for Duchenne muscular dystrophy.
On Thursday, though, Sarepta’s CEO Doug Ingram ended any speculation on the topic, by announcing the company would defer its Phase III study altogether.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.